FDA approves Biocon's generic Victoza, the fifth such application

The Food and Drug Administration approved a generic version of Victoza made by Biocon Pharma on March 11, 2026, under application number ANDA215245 ^[1]. The product is set to be first marketed on April 25, 2026, according to the FDA's drug database ^[1]. This is the fifth abbreviated new drug application, or ANDA, referencing Victoza to win approval, joining an authorized generic already sold by Teva [source summary].

The approved product is liraglutide injection, 18 milligrams per 3 milliliters, or 6 milligrams per milliliter, delivered as a solution for injection under the skin ^[1]. The FDA's records list the drug as a GLP-1 receptor agonist, the same drug class as brand-name products like Ozempic, Wegovy, and Rybelsus, though those contain a different active ingredient, semaglutide ^[1]. Victoza's active ingredient is liraglutide, an earlier GLP-1 drug that Novo Nordisk brought to market before semaglutide and tirzepatide products arrived ^[1].

FDA records show the application had a standard review priority and was approved through a single original submission, marked as approved on March 11, 2026 ^[1]. The therapeutic equivalence code listed for the product is AP1, which the FDA uses to indicate the generic is considered equivalent to the reference drug in certain respects ^[1]. Biocon Pharma Inc. is listed as the manufacturer, with Biocon Pharma as the sponsor of the application ^[1].

Why it matters for patients

More generic versions of a drug typically mean more competition among manufacturers, which can affect pricing and availability, though the sources here do not include pricing information for this specific product ^[1]. Patients using Victoza or considering it may eventually have more options for where they get the drug, since a fifth generic manufacturer plus an existing authorized generic from Teva means at least six versions of the same liraglutide product could be available in the market [source summary]. This is separate from newer drugs like Ozempic, Wegovy, Mounjaro, Zepbound, or Foundayo (orforglipron), which use different active ingredients and are not directly affected by this approval.

It is not yet known from these sources what price this generic will carry, how it compares to other liraglutide generics already on the market, or how insurance coverage might treat it. Patients with questions about switching from a brand-name product to a generic, or about which liraglutide product their insurance covers, would need to check with their pharmacist, prescriber, or insurance plan, since none of that information appears in the available records.

What happens next

According to the FDA database, this generic liraglutide product is scheduled to be first marketed on April 25, 2026, about six weeks after its approval date ^[1]. No further regulatory milestones or additional generic applications tied to Victoza are described in the available sources. Whether additional manufacturers file new applications, or whether pricing shifts as more generics enter the market, is not addressed in the information provided here.